This site’s position on GLP-1 drugs has been clear from the start: fix the inputs first. Eat nutrient-dense food, train with resistance, and let your body regulate appetite without pharmaceutical override. That was not a popular stance. Now the 2025 data is in, and the concern was not overstated.
The question was never whether semaglutide causes weight loss. It does. The question was what kind of weight you lose.
The Sarcopenia Accelerator#
A 2025 retrospective cohort study examined semaglutide use in older adults with type 2 diabetes and found that the drug accelerated sarcopenia — not just muscle mass decline but functional decline. Grip strength dropped. Physical performance declined. In a population already losing 1-2% of muscle mass per year from aging, semaglutide made the trajectory worse.
This is the demographic most likely to be prescribed the drug. Older adults with T2D and obesity are exactly the patients whose physicians are reaching for semaglutide. And they are exactly the patients who can least afford to lose muscle tissue. Sarcopenia in this population predicts falls, fractures, loss of independence, and earlier death.
The Lean Mass Numbers#
A 2025 narrative review across multiple GLP-1 studies found that up to 40% of total weight lost on GLP-1 receptor agonists is lean mass. Not fat. Lean tissue — muscle, organ mass, bone mineral content.
Run the math on a typical semaglutide outcome. A patient loses 15 kg. If 40% of that is lean mass, that is 6 kg of muscle gone. For a 70 kg man over 40 who started with maybe 28 kg of skeletal muscle, that is a 21% reduction in muscle tissue. The scale moves in the right direction. The body composition moves in the wrong one.
You do not get that muscle back easily. Rebuilding lean mass after 40 is slower, harder, and requires more protein and training stimulus than maintaining it ever did. Losing it to a drug that was supposed to improve your health is a trade most patients were never told they were making.
The SEMALEAN Counter-Evidence#
Intellectual honesty matters more than narrative convenience. The SEMALEAN study, also published in 2025, complicates the picture. In patients with sarcopenic obesity — defined as low muscle mass relative to body fat — semaglutide treatment actually improved handgrip strength and reduced the prevalence of sarcopenic obesity.
How do you reconcile this with the data above? Context. The SEMALEAN population had sarcopenic obesity at baseline, meaning their excess adiposity was itself impairing muscle function. Losing fat in that context can improve relative strength and functional capacity even if absolute lean mass also decreases. The ratio shifts favorably.
This does not invalidate the sarcopenia concern. It narrows it. For patients who are severely obese and functionally impaired by that obesity, GLP-1s may improve the muscle-to-fat ratio in the short term. For patients who are moderately overweight and already losing muscle from aging, the calculus is different. The context matters, and most prescriptions are not being written with that context in mind.
The Micronutrient Problem Nobody Mentions#
Weight loss drugs suppress appetite. Suppressed appetite means you eat less food. Less food means fewer micronutrients. This is not speculation — a 2025 narrative review found that GLP-1 receptor agonist therapy is associated with deficiencies in multiple micronutrients.
This creates a compounding problem. You are already losing lean mass from the drug. Now you are also depleting the micronutrients required to maintain the lean mass you have left. Zinc for protein synthesis. Magnesium for muscle contraction. B12 for energy metabolism. Iron for oxygen transport to working tissue.
The original article made the case that most men over 40 are already deficient in these nutrients before they start a GLP-1. The drug makes the deficit worse. You are suppressing the signal (hunger) while deepening the underlying problem (nutrient depletion) that was driving the signal in the first place.
The Counter-Protocol#
The research is clear on what mitigates GLP-1-associated muscle loss, even for patients already on the drug. A 2024 review recommended high-protein intake combined with resistance training as the primary strategy to preserve lean mass during GLP-1 therapy.
High protein. Resistance training. That is the mitigation strategy the literature recommends for people on the drug. It is also the protocol this site has been publishing since day one — without the drug.
The CRON framework targets 30g+ protein per serving from whole-food anchors: beef, salmon, eggs, chicken thighs. Every meal is built around a protein source that also delivers the micronutrients GLP-1 patients are losing. The minimum effective kettlebell program provides the resistance stimulus three days a week — the exact type of training the literature says preserves lean mass.
You can take the drug and then add protein and resistance training to counteract its side effects. Or you can use protein and resistance training as the primary intervention and skip the side effects entirely.
What You Actually Lose#
The 2025 data does not say GLP-1s are useless. They are effective weight loss drugs. For patients with severe obesity, diabetes complications, or cardiovascular risk that demands immediate weight reduction, they may be appropriate tools.
But the data does say that the weight you lose is not all fat. Up to 40% is lean mass. The drug accelerates sarcopenia in the population most vulnerable to it. It depletes micronutrients in people who were already deficient. And the mitigation strategy the research recommends — high protein and resistance training — is the same protocol that works without the drug.
The question was never whether GLP-1s work for weight loss. They do. The question is whether the weight you lose is the weight you want to lose.
For most men over 40 who are 20 to 40 pounds overweight, eating processed food, not training, and deficient in half a dozen micronutrients — the answer is to fix the inputs first. Eat real food. Lift heavy things. Fill the gaps. Let your body do what it was built to do before you override it with a drug.
The data is in. The inputs still come first.
New and seasonal recipes, and what's working. Once a month. No ads, no fluff.